Effect of Laparoscopic Cholecystectomy on Risk of Metabolic Syndrome

Sponsor
Brothers Hospitallers Hospital in Cracow (Other)
Overall Status
Recruiting
CT.gov ID
NCT05557669
Collaborator
Jagiellonian University (Other)
400
1
2
49.3
8.1

Study Details

Study Description

Brief Summary

Prospective cohort study. POPULATION: patients with gallstone disease qualified for laparoscopic cholecystectomy INTERVENTION: patients undergoing cholecystectomy for gallstones COMPARISON: gallstone disease without surgery in an observation period OUTCOME: metabolic syndrome symptoms evaluated in 3 months period The main inclusion criteria is cholelithiasis confirmed by ultrasound examination in patients between 18-75 years old. The main exclusion criteria are metabolic syndrome, diabetes, thyroid diseases, pancreatic diseases, serious abdominal surgeries in the past, pregnancy, and lactation. Participants who qualified for laparoscopic cholecystectomy in 3 months are included in the investigation group. Those not having cholecystectomy planned in the upcoming three months for any reason (no consent for surgery, long term) are included in the control group. The intervention is to assess all metabolic syndrome criteria (blood pressure, glucose tolerance, dyslipidemia, abdominal obesity) before and three months after surgery. The endpoint is to evaluate if the risk of metabolic syndrome after cholecystectomy is higher than in patients with gallstones.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Laparoscopic cholecystectomy
N/A

Detailed Description

Laparoscopic cholecystectomy is well known as a gold standard of treatment for gallstone disease. Gallbladder removal is one of the most common procedures in the United States, with more than 1.2 million cholecystectomies per year, and 92% of the procedures are performed laparoscopically. In 2011 Amigo et al. reported increased triglyceride levels in mice after cholecystectomy. According to Ruhl et al. (2013), cholecystectomy is associated with an increased risk of non-alcoholic fatty liver disease that is considered a liver manifestation of metabolic syndrome. In 2014, Shen et al. published a retrospective study enrolling 5672 participants that demonstrated an increased risk of metabolic syndrome after cholecystectomy compared with gallstone disease alone. Metabolic syndrome (MS) is a disease of civilization. It is a group of disorders containing impaired glucose intolerance, hypertension, abdominal obesity, and dyslipidemia. According to meta-analysis, individuals reaching the criteria of metabolic syndrome have a twice higher risk of myocardial infarction or stroke and a 1,5-times higher risk of death for any reason. The study aims to assess the risk of metabolic syndrome after laparoscopic cholecystectomy prospectively.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Effect of Laparoscopic Cholecystectomy on Risk of Metabolic Syndrome
Actual Study Start Date :
Feb 17, 2021
Anticipated Primary Completion Date :
Mar 30, 2025
Anticipated Study Completion Date :
Mar 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Investigation Group

Patients undergoing laparoscopic cholecystectomy for cholelithiasis

Procedure: Laparoscopic cholecystectomy
Laparoscopic cholecystectomy is a procedure of removal of the gallbladder and a gold standard in treatment of gallstone disease.

No Intervention: Control group

Patients with gallstone disease who are not planned for laparoscopic cholecystectomy in upcoming 3 months

Outcome Measures

Primary Outcome Measures

  1. Risk of the metabolic syndrome in patients undergoing laparoscopic cholecystectomy [3 months]

    Evaluated with the rNCEP criteria for metabolic syndrome.

  2. incidence of central obesity [3 months]

    waist circumference in cm: men more or equal 102 cm; women more or equal 88 cm

  3. incidence of triglyceridemia [3 months]

    serum triglycerides level in mg/dl: more or equal 150 mg/dl

  4. incidence of dyslipidemia [3 months]

    serum high-density lipo-protein (HDL) level in md/dl: men less than 40 mg/dl; women less than 50 mg/dl

  5. incidence of systemic hypertension [3 months]

    blood preassure in mm Hg: more or equal 130 mm Hg/more or equal 85 mm Hg

  6. incidence of glucose intolerance [3 months]

    fasting serum glucose in mg/dl: more or equal 100 mg/dl

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • cholelithiasis
Exclusion Criteria:
  • metabolic syndrome

  • obesity

  • diabetes

  • thyroid disease

  • pancreatic disease

  • serious abdominal surgeries in the past

  • pregnancy, lactation

Contacts and Locations

Locations

Site City State Country Postal Code
1 Brothers Hospitallers Hospital in Cracow Kraków Lesser Poland Poland 31061

Sponsors and Collaborators

  • Brothers Hospitallers Hospital in Cracow
  • Jagiellonian University

Investigators

  • Study Chair: Mirosław Szura, prof., Jagiellonian University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Zofia Orzeszko, Principal Investigator, Brothers Hospitallers Hospital in Cracow
ClinicalTrials.gov Identifier:
NCT05557669
Other Study ID Numbers:
  • 1072.6120.25.2021
First Posted:
Sep 28, 2022
Last Update Posted:
Sep 28, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 28, 2022